- Email: [email protected]
Home Study CME Enrollment Form
Home Study CME Enrollment Form Program Description and Objectives: The Journal of Urology® Home Study Course is a comprehensive learning activity developed by a team of educators, academicians and clinicians. After completing this activity, participants will be able to assess their knowledge of urology, demonstrate an increased knowledge base of urology, and apply the increased knowledge to improve the quality of patient care. Program Format: Two volumes of The Journal of Urology® are published annually. Each volume is comprised of 6 issues. Five clinically relevant articles are selected by the editor to be offered for CME in each issue of The Journal. For CME credit, the participant must read the articles and answer 5 related questions on the examination; enroll in the home study program; and submit answers online at www.AUAnet.org/cme. Click on CME Test. Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AUA takes responsibility for the content, quality, and scientific integrity of this CME activity. Credit Designation: The American Urological Association designates this educational activity for a maximum of 24.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Completion of each test and a score of 80% or above qualify for 2.00 credits of AMA PRA Category 1 Credits™ with up to a maximum of 24.00 credits annually. Original lessons of The Journal of Urology® created and released: issue month 2009; expires: issue month 2012. Target Audience: This home study program is designed for practicing physicians, Board candidates and/or residents. AUA Disclosure Policy: As a provider accredited by the ACCME, the AUA must insure balance, independence, objectivity and scientific rigor in all its activities. All faculty participating in an educational activity provided by the AUA are required to disclose to the audience any relevant financial relationships with any commercial interest to the provider. The intent of this disclosure is not to prevent faculty with relevant financial relationships from serving as faculty, but rather to provide members of the audience with information on which they can make their own judgments. The AUA must resolve any conflicts of interest prior to the commencement of the educational activity. It remains for the audience to determine if the faculty’s relationships may influence the educational content
with regard to exposition or conclusion. When unlabeled or unapproved uses of drugs or devices are discussed, these are also indicated. Unlabeled or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to unlabeled or unapproved uses or drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses. Evidence-Based Content: As a provider of continuing medical education accredited by the ACCME, it is the policy of the AUA to review and certify that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias. Disclaimer: The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA. Copyright: © American Urological Association, 2009 System Requirements for Online Test: Windows 98, 2000, XP and above or Mac OS 9 and above. Internet access. AUA Privacy and Confidentiality Policy: http://www.auanet.org/cme/onlineeduconf.cfm Program Enrollment: There are 3 convenient ways to enroll in The Journal of Urology® Home Study Course. ●
●
●
Complete the form below and return by MAIL including a check or credit card information Complete the form below and return by FAX including your credit card information Enroll online at www.auanet.org. Select The Journal of Urology®. You will need your AUA identification number, password and credit card to purchase this home study product.
The cost for the home study is $60 per year for 2007 to 2009, which includes volumes 177 to 182. Previous home study volumes may be ordered by calling 1-866-746-4282, ext 3747. Email the AUA Office of Education with any questions at [email protected] or [email protected].
The Journal of Urology® Home Study Course Enrollment Form Volume # $60 subscription cost per year includes online posttest Maximum of 24 AMA PRA Category 1 Credits™ annually Name: Address: City:
State:
( ) Check enclosed for $ Charge to
( ) VISA
Zip:
payable to: American Urological Association Education and Research, Inc.
( ) MasterCard
( ) AMEX
Card Number:
Exp. Date:
Signature: Please mail or fax registration form to:
0022-5347/09/1826-2988/0 THE JOURNAL OF UROLOGY® Copyright © 2009 by AMERICAN UROLOGICAL ASSOCIATION
2988
www.jurology.com
American Urological Association Education and Research, Inc. 1000 Corporate Blvd. Linthicum, MD 21090 Telephone: 1-410-689-3934 Fax: 1-410-689-3937
Vol. 182, 2988-2989, December 2009 Printed in U.S.A. DOI:10.1016/j.juro.2009.09.028
2989
CME QUESTIONS FOR DECEMBER 2009 ISSUE OF THE JOURNAL OF UROLOGY ® 1.
CONDITIONAL SURVIVAL PREDICTIONS AFTER NEPHRECTOMY FOR RENAL CELL CARCINOMA (vol. 182, pp. 2607–2612) On average, first and second year disease specific survival of patients treated with nephrectomy increases by: a) b) c) d) e)
2.
2.5% and 2.5%, respectively 2.5% and 5% 5% and 5% 10% and 10% 15% and 15%
UPPER URINARY TRACT RECURRENCE AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER—WHO IS AT RISK? (vol. 182, pp. 2632–2637) On univariate analysis which factor is not a predictor of upper urinary tract recurrence after radical cystectomy for bladder cancer? a) b) c) d) e)
3.
history of carcinoma in situ nontransitional cell carcinoma bladder cancer history of recurrent bladder cancer tumor involvement of the distal ureter in the cystectomy specimen cystectomy for noninvasive bladder cancer
COST-EFFECTIVENESS OF SACRAL NEUROMODULATION VERSUS INTRAVESICAL BOTULINUM A TOXIN FOR TREATMENT OF REFRACTORY URGE INCONTINENCE (vol. 182, pp. 2799 –2804) Intravesical botulinum injection is considered cost-effective when compared to sacral neuromodulation over which time period? a) b) c) d) e)
4.
1 2 3 4 5
year years years years years
SAFETY AND TOLERABILITY OF SOLIFENACIN ADD-ON THERAPY TO ␣-BLOCKER TREATED MEN WITH RESIDUAL URGENCY AND FREQUENCY (vol. 182, pp. 2825–2830) The most efficacious medical therapeutic option to treat overactive bladder symptoms in men with lower urinary tract symptoms is: a) b) c) d) e)
5.
antimuscarinics ␣-blockers 5␣-reductase inhibitors luteinizing hormone-releasing hormone agonists phosphodiesterase type 5 inhibitors
RISK FACTORS ASSOCIATED WITH URGE INCONTINENCE AFTER CONTINENCE SURGERY (vol. 182, pp. 2805–2809) Which of the following is not associated with higher rates of urge incontinence requiring treatment after continence surgery? a) b) c) d) e)
urge incontinence symptoms prior continence surgery detrusor overactivity fascial sling antimuscarinic therapy
Publication date: December 2009 Expiration date: December 2012
with regard to exposition or conclusion. When unlabeled or unapproved uses of drugs or devices are discussed, these are also indicated. Unlabeled or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to unlabeled or unapproved uses or drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses. Evidence-Based Content: As a provider of continuing medical education accredited by the ACCME, it is the policy of the AUA to review and certify that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias. Disclaimer: The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA. Copyright: © American Urological Association, 2009 System Requirements for Online Test: Windows 98, 2000, XP and above or Mac OS 9 and above. Internet access. AUA Privacy and Confidentiality Policy: http://www.auanet.org/cme/onlineeduconf.cfm Program Enrollment: There are 3 convenient ways to enroll in The Journal of Urology® Home Study Course. ●
●
●
Complete the form below and return by MAIL including a check or credit card information Complete the form below and return by FAX including your credit card information Enroll online at www.auanet.org. Select The Journal of Urology®. You will need your AUA identification number, password and credit card to purchase this home study product.
The cost for the home study is $60 per year for 2007 to 2009, which includes volumes 177 to 182. Previous home study volumes may be ordered by calling 1-866-746-4282, ext 3747. Email the AUA Office of Education with any questions at [email protected] or [email protected].
The Journal of Urology® Home Study Course Enrollment Form Volume # $60 subscription cost per year includes online posttest Maximum of 24 AMA PRA Category 1 Credits™ annually Name: Address: City:
State:
( ) Check enclosed for $ Charge to
( ) VISA
Zip:
payable to: American Urological Association Education and Research, Inc.
( ) MasterCard
( ) AMEX
Card Number:
Exp. Date:
Signature: Please mail or fax registration form to:
0022-5347/09/1826-2988/0 THE JOURNAL OF UROLOGY® Copyright © 2009 by AMERICAN UROLOGICAL ASSOCIATION
2988
www.jurology.com
American Urological Association Education and Research, Inc. 1000 Corporate Blvd. Linthicum, MD 21090 Telephone: 1-410-689-3934 Fax: 1-410-689-3937
Vol. 182, 2988-2989, December 2009 Printed in U.S.A. DOI:10.1016/j.juro.2009.09.028
2989
CME QUESTIONS FOR DECEMBER 2009 ISSUE OF THE JOURNAL OF UROLOGY ® 1.
CONDITIONAL SURVIVAL PREDICTIONS AFTER NEPHRECTOMY FOR RENAL CELL CARCINOMA (vol. 182, pp. 2607–2612) On average, first and second year disease specific survival of patients treated with nephrectomy increases by: a) b) c) d) e)
2.
2.5% and 2.5%, respectively 2.5% and 5% 5% and 5% 10% and 10% 15% and 15%
UPPER URINARY TRACT RECURRENCE AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER—WHO IS AT RISK? (vol. 182, pp. 2632–2637) On univariate analysis which factor is not a predictor of upper urinary tract recurrence after radical cystectomy for bladder cancer? a) b) c) d) e)
3.
history of carcinoma in situ nontransitional cell carcinoma bladder cancer history of recurrent bladder cancer tumor involvement of the distal ureter in the cystectomy specimen cystectomy for noninvasive bladder cancer
COST-EFFECTIVENESS OF SACRAL NEUROMODULATION VERSUS INTRAVESICAL BOTULINUM A TOXIN FOR TREATMENT OF REFRACTORY URGE INCONTINENCE (vol. 182, pp. 2799 –2804) Intravesical botulinum injection is considered cost-effective when compared to sacral neuromodulation over which time period? a) b) c) d) e)
4.
1 2 3 4 5
year years years years years
SAFETY AND TOLERABILITY OF SOLIFENACIN ADD-ON THERAPY TO ␣-BLOCKER TREATED MEN WITH RESIDUAL URGENCY AND FREQUENCY (vol. 182, pp. 2825–2830) The most efficacious medical therapeutic option to treat overactive bladder symptoms in men with lower urinary tract symptoms is: a) b) c) d) e)
5.
antimuscarinics ␣-blockers 5␣-reductase inhibitors luteinizing hormone-releasing hormone agonists phosphodiesterase type 5 inhibitors
RISK FACTORS ASSOCIATED WITH URGE INCONTINENCE AFTER CONTINENCE SURGERY (vol. 182, pp. 2805–2809) Which of the following is not associated with higher rates of urge incontinence requiring treatment after continence surgery? a) b) c) d) e)
urge incontinence symptoms prior continence surgery detrusor overactivity fascial sling antimuscarinic therapy
Publication date: December 2009 Expiration date: December 2012